Indication
Acute Myeloid Leukemia with FLT3 Mutation
3 clinical trials
11 products
Clinical trial
A Phase II, Open-label, Single Arm Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Twice Daily Midostaurin (PKC412) Combined With Standard Chemotherapy and as a Single Agent Post-consolidation Therapy in Children With Untreated FLT3-mutated AMLStatus: Recruiting, Estimated PCD: 2025-08-18
Product
MidostaurinProduct
FludarabineProduct
CytarabineProduct
DaunorubicinProduct
MitoxantroneProduct
EtoposideClinical trial
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction ChemotherapyStatus: Recruiting, Estimated PCD: 2028-07-31
Product
AzacitidineProduct
GilteritinibProduct
VenetoclaxClinical trial
A Phase 1/2 Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid LeukemiaStatus: Active (not recruiting), Estimated PCD: 2021-08-25
Product
gilteritinibProduct
Idarubicin